Andere Sprachen Citius Pharmaceuticals, Inc.

Aktien

A2DXS0

US17322U2078

CTXR

Realtime-Estimate Cboe BZX Andere Börsenplätze 19:37:10 26.04.2024			% 5 Tage	% 1. Jan.
0.653 ^USD	-10.87%		-12.62%	-12.86%

16:45	Citius Pharmaceuticals startet 15 Millionen Dollar Emission	MT
11.04.	Citius Pharmaceuticals, Inc. gibt die Aufnahme von City of Hope in die Phase-1-Studie von LYMPHIR in Kombination mit CAR-T zur Behandlung von B-Zell-Lymphomen an der UMN bekannt	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Citius Pharmaceuticals Launches $15 Million Offering	16:45
Citius Pharmaceuticals Announces $15 Million Registered Direct Offering	14:01
Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma	11.04.
Citius Pharmaceuticals, Inc. Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma	11.04.
Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference	04.04.
Citius Pharmaceuticals, Inc. Announces FDA Acceptance of the BLA Resubmission of LYMPHIR (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma	18.03.
Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma	18.03.
Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program	07.03.
Citius Pharmaceuticals to Participate In Upcoming BIO CEO and Sidoti Investor Conferences	26.02.
Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration	26.02.
Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor Conferences	23.02.
Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma	15.02.
Citius Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	14.02.
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update	14.02.
Sector Update: Health Care Stocks Gain Late Afternoon	14.02.
Citius Pharmaceuticals Resubmits Application for Lymphoma Treatment	14.02.
Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma	14.02.
Citius Pharmaceuticals, Inc. Announces the Resubmission of the Biologics License Application to the U.S. Food and Drug Administration for Lymphir	14.02.
Citius Pharmaceuticals Announces Nomination of Pharmaceutical Executive Robert J. Smith to its Board of Directors	23.01.
North American Morning Briefing : Stock Futures Extend Losses as FOMC Minutes Awaited	03.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Citius Pharmaceuticals, Inc.

Aktien

A2DXS0

US17322U2078

CTXR

Andere Sprachen

Filter